Chromium — Research Profile

The evidence is moderately positive. Meta-analyses show small but statistically significant improvements in fasting glucose and HbA1c in people with type 2 diabetes, particularly at doses of 200-1,000mcg chromium picolinate ^[2][8]. However, effects are modest (HbA1c reduction of about 0.5%) and should not replace standard diabetes medications. It may be most helpful for those with chromium-poor diets.

Chromium picolinate is generally safe at doses up to 1,000mcg/day. Early concerns about potential DNA damage from picolinate were based on cell culture studies and have not been replicated in human research. Thousands of study participants have taken chromium picolinate without serious adverse effects. However, those with kidney disease should use caution.

Effects on weight are minimal. A meta-analysis found chromium picolinate produced an average weight loss of only 0.5 kg (about 1 pound) compared to placebo. It may help reduce carbohydrate cravings in some individuals, but should not be relied upon as a primary weight loss strategy.

Chromium picolinate is the most-studied form and is better absorbed (about 1.2%) than chromium chloride (about 0.4%), which is why most diabetes and weight-loss trials used picolinate. No head-to-head trial establishes one form as clinically superior for outcomes, and a Cochrane review of chromium picolinate for weight loss found effects of debatable clinical relevance. The choice mainly reflects absorption and the depth of the evidence base rather than any proven therapeutic advantage.

Chromium's established role is as a trace mineral involved in normal carbohydrate and lipid metabolism, but frank deficiency is essentially unreported in healthy people. Meta-analyses show only small effects on glucose control (modest reductions in fasting glucose and HbA1c of unclear clinical importance) and about 0.75 kg average weight loss with roughly a 0.40 kg/m2 BMI reduction. The American Diabetes Association does not recommend routine chromium supplementation for glucose management.

The Adequate Intake is 35 mcg/day for men and 25 mcg/day for women aged 19-50, dropping to 30 and 20 mcg for those 51 and older, and these amounts are easily met from a normal diet. Clinical trials in type 2 diabetes used far higher supplemental doses, commonly 200-1,000 mcg/day, with the landmark trial using 1,000 mcg/day. No therapeutic dose is officially established, and the benefits at these higher doses remain modest.

No trial has directly compared times of day for chromium, so an optimal schedule has not been established. Because antacids and calcium carbonate reduce its absorption while vitamin C enhances it, separating chromium from antacids and taking it with a meal or a vitamin C source is a reasonable practical approach. Any timing effect is likely small relative to the supplement's overall modest impact.

At the microgram doses typical of supplements, reported side effects are uncommon and mild. Higher supplemental doses have been linked in isolated case reports to hypoglycemia and dermatitis, plus rare serious events including weight loss, anemia, thrombocytopenia, liver dysfunction, renal failure, and rhabdomyolysis. People taking chromium alongside diabetes medication should watch for symptoms of low blood sugar.

Chromium can add to the glucose-lowering effect of insulin and antidiabetic drugs such as metformin, increasing the risk of hypoglycemia. It can also reduce levothyroxine absorption when taken within about 6 hours of the thyroid dose. Aspirin and NSAIDs increase chromium absorption, while antacids decrease it, so spacing these medications from chromium is sensible.

Because chromium deficiency is essentially unreported in healthy people eating a normal diet, routine supplementation is unnecessary for most. People with type 2 diabetes or polycystic ovary syndrome are the most-studied groups, but the effects on glucose are modest and the American Diabetes Association does not endorse routine use. Anyone taking antidiabetic medication who tries chromium should account for its additive glucose-lowering effect.

In the main type 2 diabetes trial, improvements in fasting glucose and insulin were measured at 2 and 4 months of daily supplementation, not within days. Meta-analyses of glucose and lipid endpoints pool trials that typically ran 8-16 weeks, so any measurable metabolic change should be judged over roughly 2-3 months rather than short-term. Chromium is not a fast-acting supplement, and its effects even over months are modest.

The Food and Nutrition Board set no Tolerable Upper Intake Level for trivalent (supplemental) chromium because no adverse effects have been reliably linked to high intakes from food or supplements, though it noted the underlying data are limited. Most controlled trials ran only up to about 4 months, so safety beyond a few months is not well characterized. Isolated case reports at high supplemental doses describe kidney and liver injury, so open-ended high-dose use is not fully reassured by the evidence.

Trivalent chromium in supplements has low toxicity and no established Tolerable Upper Intake Level, and it should not be confused with industrial hexavalent chromium, which is a recognized toxin. At high supplemental doses, isolated case reports have linked chromium to hypoglycemia, kidney failure, liver dysfunction, and rhabdomyolysis. Very high intakes are therefore not risk-free even though a formal upper limit has not been defined.

Chromium absorption is enhanced by vitamin C and reduced by calcium carbonate and other antacids, so spacing it from mineral antacids matters more than most supplement pairings. If it is stacked with other blood-sugar-lowering supplements, the additive glucose-lowering effect can raise the risk of hypoglycemia. There is no evidence that combining chromium with other supplements improves its own modest effects.

Products list chromium as picolinate, chloride, or nicotinate/polynicotinate; picolinate is absorbed at about 1.2% versus roughly 0.4% for chromium chloride, though the ODS notes absorption of the various forms is broadly similar. There is no established therapeutic dose or standardization requirement for chromium supplements. Check the amount of elemental chromium in micrograms, since the Adequate Intake for adults is only 25-35 mcg per day.